Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
This study has been completed.
Study NCT00000353   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: June 23, 2005   History of Changes

September 20, 1999
June 23, 2005
 
 
 
 
Complete list of historical versions of study NCT00000353 on ClinicalTrials.gov Archive Site
 
 
 
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.

 
Phase II
Interventional
Treatment
  • Opioid-Related Disorders
  • Substance-Related Disorders
Drug: Buprenorphine/naloxone
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Both
19 Years to 57 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000353
 
NIDA-3-0012-2, Y01-3-0012-2
National Institute on Drug Abuse (NIDA)
University of Pennsylvania
Principal Investigator: Charles O'Brien, M.D., Ph.D. PDVAMC Treatment Research Center
National Institute on Drug Abuse (NIDA)
December 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP